DIagnoSing Care hOme UTI Study

Urinary Tract Infections Clinical Trial

— DISCO UTI  

Official title:

Feasibility Cohort Study on Predictors of Diagnosis and Prognosis of Urine Infection in Care Home Residents: DIagnoSing Care hOme UTI Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05880329
• Other study ID #: 79003
• Status: Not yet recruiting
• Start date: September 1, 2023
• Est. completion date: January 31, 2024

Study information

• Verified date: August 2023
• Source: University of Southampton
• Contact: Abigail Moore
• Phone: 00441865289300
• Email: abigail.moore[@]phc.ox.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The number of care home residents is increasing and urinary tract infections (UTIs) are common amongst this group. Accurate diagnosis of UTI is important because not treating an infection may lead to serious consequences including death. However, giving antibiotic treatment when there isn't an infection causes side effects and antibiotic resistance, making future infections harder to treat. Unfortunately, there are several challenges that mean that it is difficult to diagnose UTI accurately in care home residents. Firstly, UTIs don't always cause clear symptoms for people who live in care homes. They sometimes just cause symptoms like confusion which can have lots of different possible causes. Secondly, it may be hard for people living with dementia to say how they are feeling or to easily provide a urine sample. Thirdly, many people who live in care homes have bacteria present in their urine even when they are well, but this not harmful and does not need treatment. Finally, urine tests that are currently available do not give accurate or quick results. We have thought about some new ways that might help show us if someone in a care home really has a UTI but we don't know yet whether these will work. Our ideas include 1) Working out which symptoms or signs mean a UTI is more likely 2) Detecting new markers of infection in urine samples and 3) Trying out new bedside tests that give rapid results. For this study we plan to recruit 100 care home residents who will be followed up over 6 months. All 100 participants will provide information and a urine sample at the beginning of the study. 25 of these participants will also provide repeated weekly samples for 4 weeks to look at any changes in the urine over time. Additional information and urine samples will be collected if a participant develops a possible UTI during the study and any treatments will be recorded. Our findings will be used to develop a funding application for a larger study aiming to improve the diagnosis of UTI in care home residents.

Description:

This feasibility observational study will be conducted in four overlapping stages: recruiting a cohort of 100 care home residents (CHR) from up to 10 care homes across the Thames Valley and Wessex (Stage 1); collecting weekly repeated baseline urine samples from a subset of participants (without suspected UTI) (Stage 2); following all 100 participants for 6 months and collecting additional data on those who develop possible UTI (Stage 3), and interviewing participants, their families and care home staff about study feasibility and acceptability (Stage 4). Stage 1 - Cohort recruitment and baseline data collection Baseline assessments: Following consent, baseline data will be collected including demographics, medical history, and a description of baseline functional ability. We will also collect a urine sample for baseline microbiological and urinary biomarker analyses for each participant. Stage 2 - Repeat urine sampling cohort 25 CHR recruited in Stage 1 will be asked to provide weekly urine samples for four weeks. Urine samples will be sent for microbiological and urinary biomarker analyses. CHR who develop a possible UTI during this stage will contribute to Stage 3 and will continue to have any remaining weekly samples collected if possible. Stage 3 - Possible UTI episodes All 100 CHR recruited during Stage 1 will be followed for 6 months. Care home staff will be asked to alert the research team as soon as any participant in the cohort develops possible UTI. This would include any situation where care home staff have decided to consult with a healthcare professional because they have detected a change in the CHR or their urine and believe that a UTI is 'a likely cause'. This would not include residents who become acutely unwell from a source that is clearly not UTI at onset (e.g. chest or skin infection or cerebrovascular event). Participants who experience possible UTI will have a 'symptomatic baseline' assessment and follow up visits at 14 and 28 days. A urine sample will be collected. If possible and this doesn't delay care, this will be before any treatment is initiated. Repeat urine samples will be collected at days 14 and 28. Some of the urine taken at symptomatic baseline and day 28 will also be tested using one or more novel POCTs by a member of the research team. Stage 4 - Qualitative sub-study We will conduct a qualitative evaluation to explore study acceptability and barriers and facilitators to study procedures. Care home staff, residents, and their families will be asked to participate in semi-structured interviews towards the end of the study period.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: January 31, 2024
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Willing and able to give informed consent for the study, or if lacking capacity, a consultee willing to complete a consultee declaration form.
• Permanently living in a care home (nursing, residential or mixed).
• Aged 65 or over.

Exclusion Criteria:

• Current/recent suspected UTI (within last 4 weeks). However, may be reassessed for eligibility after 4 weeks.
• Temporary/respite resident (unlikely to remain living in the care home for the 6 months of the study duration)
• Terminal illness limiting life expectancy such that inclusion would be inappropriate (as judged by care home staff).
• Known to have a medical condition or be on treatment that is likely to result in severe impairment of the immune system. For example, neutropenia, recent cancer chemotherapy or radiotherapy, or long-term use of oral steroids or other immunosuppressant medication.
• Experiencing faecal incontinence to the extent that it is impossible to obtain an uncontaminated urine sample (as determined by care home staff).
• Indwelling urinary catheter or regular use of intermittent catheterisation.
• Structural urological abnormalities. For example, renal polycystic disease, horseshoe kidney, hydronephrosis, renal hypoplasia
• Current renal tract malignancy. However, residents with prostate cancer will be eligible if they do not require catheterisation and are not considered terminally ill.

Related Conditions & MeSH terms

• Infections
• Urinary Tract Infections

Intervention

Diagnostic Test:
• Candidate POCTs for detecting UTI
POCT performance will be evaluated in participants who experience possible UTI.

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
University of Southampton	Public Health Wales, University of Bristol, University of Oxford

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	As a feasibility study, there is no primary outcome measure.		Baseline
Secondary	Proportion of care homes agreeing to participate when recruiting care homes as research sites.		Baseline
Secondary	Proportion of residents screened that are eligible and proportion of eligible that are recruited.		Baseline
Secondary	Proportion of baseline urine samples obtained from participants recruited (consented)		Baseline
Secondary	Proportion of repeated urine samples obtained of those participating in Stage 2		2, 3 and 4 weeks
Secondary	Quality of urine samples obtained	Proportions of samples collected mid-stream clean catch, vs other collection techniques Proportions of samples contaminated (as reported by staff collecting samples) Proportions of samples with microbiological evidence of contamination	Through study completion, 6 months
Secondary	Adherence to urine transport protocols	Time from sampling until receipt in laboratory Proportion recorded as stored refrigerated prior to transportation	Through study completion, 6 months
Secondary	Proportion of residents that experience a possible UTI during the follow-up period that are reported to the research team.		Through study completion, 6 months
Secondary	Proportion of residents with possible UTI that are not reported to the research team.		Assessed weekly through to study completion at 6 months
Secondary	Proportion of residents with possible UTI in whom the following is obtained:	Symptomatic baseline data on the characteristics of the possible UTI; A urine sample at onset of possible UTI; A urine sample prior to any antibiotic administration; Follow-up data; Follow-up urine samples at 14 and 28 days from symptom onset	Through study completion, 6 months
Secondary	Using semi-structured interviews with qualitative analysis to describe the views of care home staff, participants and family members on:	Barriers and facilitators to taking part in the study.; Experience of obtaining/giving consent.; Experience of being a participant/family member of a participant.; Experience of giving/collecting urine samples including resident and staff willingness and capacity to obtain weekly urine samples.; Experience of reporting a possible UTI to the study team and any barriers or facilitators to reporting in a timely fashion.; The diagnosis of UTI and how this is determined in usual care; The diagnosis of UTI and how this was determined during the study; Additional tests including POCTs for UTI	Through study completion, 6 months
Secondary	Participant baseline demographic characteristics predictive of subsequent possible UTI/clinical outcomes		Through study completion, 6 months
Secondary	Participant clinical characteristics at point of possible UTI and association with clinical outcomes		Through study completion, 6 months
Secondary	Changes in weekly sample microbiology	Description of any changes in the microbiological results of samples sent weekly from weeks 1-4	Baseline, 2, 3 and 4 weeks
Secondary	Predictors of weekly sample microbiology and changes in microbiology	Including previous urine culture results, resident demographic characteristics, and sampling characteristics	Baseline, 2, 3 and 4 weeks
Secondary	Association between asymptomatic bacteriuria at baseline or in weekly sampling and onset of possible UTI during follow up period		Through study completion, 6 months
Secondary	Association of each urinary biomarker with asymptomatic bacteriuria	Assess whether concentration of biomarkers listed below is associated with asymptomatic bacteriuria: Matrix metallopeptidase-9, neutrophil gelatinase associated lipocalin (NGAL), Interleukin , Interleukin 8, Interleukin 6, Interleukin 6, Interleukin 10, secretory IgA, and chemokine (C-X-C motif) ligand 1	Baseline
Secondary	Urinary biomarker concentrations in urine samples from asymptomatic participants without bacteriuria	Matrix metallopeptidase-9, neutrophil gelatinase associated lipocalin (NGAL), Interleukin , Interleukin 8, Interleukin 6, Interleukin 6, Interleukin 10, secretory IgA, and chemokine (C-X-C motif) ligand 1	Baseline
Secondary	Urinary biomarker concentrations in urine samples from possible UTI episodes	Matrix metallopeptidase-9, neutrophil gelatinase associated lipocalin (NGAL), Interleukin , Interleukin 8, Interleukin 6, Interleukin 6, Interleukin 10, secretory IgA, and chemokine (C-X-C motif) ligand 1	Through study completion, 6 months
Secondary	Failure rate of the POCT in residents with possible UTI (no result or invalid result)		Through study completion, 6 months
Secondary	Agreement between POCT result and laboratory enhanced culture result at symptom onset for each possible UTI episode, and at 28 days post symptom on set	Comparison to be made between each POCT result and the result from the enhanced culture carried out in the laboratory at symptomatic baseline and 28 day follow up of each possible UTI episode.	Through study completion, 6 months